LG Chem Obtains MFDS Approval for Diabetes New Drug Combination 'Jemidapa Tablets'

[Asia Economy Reporter Lee Gwan-joo] LG Chem announced on the 22nd that it has obtained marketing approval from the Ministry of Food and Drug Safety for 'Jemidapa Tablets,' a combination drug of Gemiglo indicated for type 2 diabetes.

Jemidapa Tablets are a two-drug combination developed by LG Chem, containing 'Gemigliptin,' the main ingredient of Gemiglo, a type 2 diabetes treatment, along with another diabetes treatment ingredient, 'Dapagliflozin.'

Gemiglo is a diabetes treatment drug that was approved as the 19th domestic new drug by the Ministry of Food and Drug Safety in 2012. With this approval, the Gemiglo product line has expanded to four products.

LG Chem expects that through the development of this combination drug, patient convenience who previously took combination therapy will be improved, and medication adherence can be enhanced.

The Gemiglo product line has continuously grown in prescription volume since it became the first domestic new drug to exceed 100 billion KRW in annual prescriptions in 2019. The outpatient prescription amount for the three Gemiglo products last year was 130.3 billion KRW, a 12% increase compared to 116.3 billion KRW in 2020.